FDA Struggles to Prevent Recurrence of Meningitis Outbreak
Learn more about the FDA Struggles to Prevent more outbreaks – READ MORE
On May 9, the FDA warned that unless it gets additional authority to regulate compounding facilities, we will likely see a recurrence of the multistate meningitis outbreak that killed nearly 50 people and sickened more than 700. In the meantime, though, the FDA has followed through on its promise to inspect “high-risk” facilities, which has already resulted in four recalls from compounding centers in Georgia, Florida, and New Jersey.
The Ongoing Impact of the Fungal Meningitis Outbreak CLICK TO READ MORE